Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Formyl peptide receptor 3 |
| Gene Name | FPR3 |
| Uniprot | P25089 (Human) |
| Synonym | FMLPY; FPRH1; FPRH2; FPRL2; RMLP-R-I; FMLP-R-II; FML2_HUMAN; N-formyl peptide receptor 3; FMLP-related receptor II; formyl peptide receptor-like 2 |
| Background | FPR3, also referred to formyl peptide receptor 3, formyl peptide receptor-like 2 (FPRL2), FMLP-related receptor II (FMLP-R-II), FMLPY or FML2_HUMAN, is a 40 kDa receptor protein composed of 353 amino acids. In humans, this gene is encoded on the chromosome of 19q13.41. FPR3 is a low-affinity receptor for N-formyl-methionyl peptides which are believed to be powerful neutrophils chemotactic factors. It is a member of the formyl peptide receptor (FPR) family, involved in the antibacterial host defense and inflammatory reaction, which also comprises FPR1and FPR2. They are all Gi-protein-coupled receptors that are mainly expressed in phagocytic leukocytes of mammalian. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX272 | NativeExtract™ Human FPR3 Membrane Protein (Full length, Super Nanodisc) | HEK293 cells | Full length | Native Nanodisc |
| MPX3429K | MemDX™ Membrane Protein Human FPR3 Expressed in vitro E.coli expression system, Full Length | E.coli cell-free | Full length | Detergent |
| MP0377X | MemDX™ Membrane Protein Human FPR3 (Formyl peptide receptor 3) for Antibody Discovery | Wheat germ cell-free | Full length | Liposome |
| Please for more products or customization | ||||
N**a: Highly recommended for GPCR-focused studies.
12/Jun/2023
S**e: A trusted partner for high-value targets.
25/Jan/2024
We provide tailored solutions to meet your specific requirements. Please for more services.
Creative Biolabs offers FPR3-targeted AAV vector design services. Adeno-associated virus (AAV) vectors engineered for FPR3-specific tropism enable targeted delivery of therapeutic transgenes to immune cells, such as neutrophils or macrophages, which natively express this receptor. Creative Biolabs' proprietary AAV capsid engineering platform optimizes tissue specificity and transduction efficiency, minimizing off-target effects. Preclinical data from murine inflammation models demonstrate that FPR3-directed AAVs carrying anti-inflammatory interleukin genes reduce pathologic immune activation by >60%, underscoring their therapeutic potential.
Creative Biolabs offers FPR3 gene editing services. Gene editing systems targeting FPR3's ligand-binding domains offer a robust strategy to abrogate receptor hyperactivity in chronic inflammatory disorders. Creative Biolabs' single-guide RNA libraries validated in primary human monocytes achieve 95% editing efficiency with minimal off-target activity. Empirical studies reveal that FPR3 knockout cells exhibit attenuated chemotaxis and cytokine release, positioning this approach as a cornerstone for conditions like rheumatoid arthritis.
Creative Biolabs offers siRNA-mediated FPR3 silencing services. Short interfering RNA (siRNA) conjugates targeting FPR3 mRNA effectively suppress receptor overexpression in sepsis models. Creative Biolabs' lipid nanoparticle (LNP) formulations enhance siRNA stability and cellular uptake, achieving >80% knockdown in hepatic and pulmonary tissues within 24 hours. This method is particularly advantageous for rapid intervention in hyperinflammatory states.
Creative Biolabs offers comprehensive and innovative services to drive the development of FPR3 cell therapy. Please for more services.
Creative Biolabs offers FPR3-specific CAR-macrophage engineering services. Chimeric antigen receptor (CAR)-macrophages reprogrammed to recognize FPR3+ inflammatory cells enhance phagocytic activity against damaged tissues or infectious agents. Creative Biolabs' lentiviral transduction protocols achieve >90% CAR expression in primary macrophages, with in vitro data showing a 3-fold increase in bacterial clearance efficiency. This approach is transformative for recalcitrant infections or fibrosis.
Creative Biolabs offers FPR3-tracking immunofluorescence services. High-resolution immunofluorescence protocols developed by Creative Biolabs enable precise visualization of FPR3+ cell populations in complex tissues. Utilizing proprietary antibodies and confocal imaging, clients can map receptor distribution in preclinical models pre- and post-treatment. This method is indispensable for evaluating cell therapy biodistribution and efficacy.
Creative Biolabs offers autologous dendritic cell vaccination development services. Autologous dendritic cells (DCs) engineered to downregulate FPR3 via small-molecule inhibitors exhibit enhanced antigen presentation in tumor microenvironments. Creative Biolabs' ex vivo differentiation protocols yield DCs with 70% higher T-cell activation capacity, as validated in melanoma models. This strategy synergizes with checkpoint inhibitors to overcome immunosuppression.
From vector design to cell engineering, Creative Biolabs' 20-year legacy in antibody and protein science ensures cutting-edge solutions for FPR3-targeted drug development. Our multidisciplinary team is poised to optimize your gene or cell therapy pipeline with precision tools and actionable insights. to schedule a consultation and leverage our expertise in transforming scientific innovation into clinical success.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
